End of Trial in All Participating Countries 13.2. End of trial is Defined as Last Subject Last Visit (LSLV). 14.SPONSOR DISCONTINUAT ION CRITERIA Prem ature termination of this study may occur because of a regulatory authority decision, change in opinion of the IRB/EC, investigational product safet y problems, or at the discretion of Pfizer. I n addition, Pfizer retains the right to discontinue developmen t of VBI R-2 at an y time. If a stud y is prematurel y terminated, Pfizer will promptly notify the investigator. After notification, the investigator must contact all participating participants and the hospital pharmacy (if applicable) within an acceptable time period per the institutional policy and IRB/EC following receipt of notification. As directed b y Pfizer, all study materials must be collected and all CRFs completed to the greatest extent possible. 15.IN THE CASE OF PREMA TURE TERMINATION (EG, THE SPONSOR DISCONTINUES DEVELOP MENT), THE STUDY WILL BE C LOSED NO LATER THAN 2 YEARS FROM TH E FIRST DOSE OF THE LAST SUBJECT.PUBLICATION OF STUDY RESULTS 15.1. Communication of Results by Pfizer Pfizer fulfills its commitment to publicly disclose clinical trial results th rough posting of the results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials Database (EudraCT), and or www.pfizer.com, along with other public registries in accordance with applicable local laws and regulations. Inall cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and complete manner and are reported regardless of the outcome of the stud y, or the country in which the study was conducted. www.clinicaltrials.gov Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer- sponsored interventional studies (conducted in participants) that evaluate the safet y and/or efficacy of a Pfizer product, regardless of the geographical location in which the study is conducted. US Basic Results are submitted for posting within 1 year of the primary completion date (PCD) for studies in adult populations or within 6 months of the PCD for studies in pediatric populations. PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 128PCD is defined as the date that the final participant was examined or received an intervention for the purposes of final collection of data for the primary outcome, whether the clinical study concluded according to the prespecified protocol or was terminated. EudraCT Pfizer posts European Union (EU) Basic Results on EudraCT for all Pfizer -sponsored interventional studies that are in scope of EU requirements. EU Basic Results are submitted for posting within 1 year of the PCD for studies in adult populations or within 6 months of the PCD for studies in pediatric po pulations. www.pfizer.com Pfizer posts Public Disclosure Sy nopses (CSR synopses in which any data that could be used to identify individual participants has been removed) on www.pfizer.com for Pfizer -sponsored interventional studies at the same time the US Basic Results document is posted to www.clinicaltrials.gov. 15.2. Publications by Investigators Pfizer supports the exercise of academic freedom and has no objection to publication by the Principal I nvestigator (PI) of the results of the study based on informat ion collected or generated b y the PI, whether or not the results are favorable to the Pfizer product. However, to ensure against inadvertent disclosure of confidential information or unprotected inventions, the investigator will provide Pfizer with an opp ortunity to review any proposed publication or other t ype of disclosure of the results of the study (collectively, “publication”) before it is submitted or otherwise disclosed. The investigator will provide any publication to Pfizer at least 30 days before it is submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual propert y rights, the investigator agrees to delay the disclosure for a period not to exceed an additional 60 days. The investigator will, on request, remove an y previously undisclosed confidential information before disclosure, except for an y study -or Pfizer product -related information necessary to the appropriate scientific presentation or understanding of the study results. If the stud y is p art of a multicenter study , the investigator agrees that the first publication is to be a joint publication covering all investigator sites, and that an y subsequent publications by the PI will reference that primary publication. However, if a joint manusc ript has not been submitted for publication within 12 months of completion or termination of the study at all participating sites, the investigator is free to publish separatel y, subject to the other requirements of this section. For all publications relat ing to the stud y, the institution will comply with recognized ethical standards concerning publications and authorship, including Section II —“Ethical Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 129Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship , established by the International Committee of Medical Journal Editors. Publication of study results is also provided for in the CSA between Pfizer and the institution. I n this sect ion entitled Publications by Investigators, the defined terms shall have the meanings given to them in the CSA. If there is an y conflict between the CSA and an y attachments to it, the terms of the CSA control. If there is an y conflict between this protocol and the CSA, this protocol will control as to any issue regarding treatment of study participants, and the CSA will control as to all other issues. PF-06936308 C3621001 Final Protocol Amendment 2, 22 Dec 2020 PFIZER CONFIDENTIAL Page 13016.REFERENCES 1. About Non-Small Cell Lung Cancer . American Cancer Society . Cancer Facts & Figures 2017. Atlanta: American Cancer Societ y; 2017. 2. About Breast Cancer . American Cancer Society. Cancer Facts & Figures 2017. Atlanta: American Cancer Society ; 2017. 3. Triple -negative Breast Cancer. Breast Cancer Organization Feb 2017. www.breastcancer.org. Accessed August 2017. 4. Foulkes WD, Smith I E, Reis - Filho JS: Triple negative breast cancer. N Engl J Med 363: 1938 -1948, 2010 2. 5. Dent R, Trudeau M, Pritchard KI, et al: Triple negative breast cancer: Clinical features and patterns of r ecurrence. Clin Cancer Res 13:4429-4434, 2007.